Table S2. MRM (Multiple reaction monitoring) parameters of the target compounds Compound name ChEBI Abbreviation ID molecular formula MW g/mole precursor ion (m/z) product ion (m/z) Dwell time CE (msec) α-Linolenoyl ethanolamide 89605 a-LEA C20H35NO2 325.5 322.4 61.9 20 -16 Palmitoleoyl ethanolamide 71465 POEA C18H35NO2 297.5 298.4 62.2 5 -16 Pentadecanoyl ethanolamide 165589 PDEA C17H35NO2 285.5 386.4 61.9 5 -15 Linoleoyl ethanolamide 64032 LEA C20H37NO2 323.5 324.3 62 20 -33 Anandamide 2700 AEA C22H37NO2 347.5 348.2 62.0 20 -23 Docosahexaenoyl ethanolamide
Table S2. Age-adjusted Incidence Rates and Incidence Rate Ratios of Overall Type II Endometrial Cancer by Race/Ethnicity for 2004–2009 (Period 1) and 2010–2015 (Period 2) N IR (95% CI) IRR (95% CI) P value Overall 2004-2009 16,229 3,27 (3.22, 3.32) 1.00 2010-2015 NHW 19,677 3.37 (3.33, 3.42) 1.03 (1.01, 1.05) 0.0032 2004-2009 11,074 3.14 (3.08, 3.20) 1.00 2010-2015 NHB 12,293 3.12 (3.07, 3.18) 1.00 (0.97, 1.02) 0.7386 2004-2009 2,481 5.63 (5.40, 5.86) 1.00 2010-2015 NHO 3,429 6.15 (5.94, 6.37) 1.09 (1.04, 1.15) 0.0012 2004-2009 1,207 2.59 (2.45, 2.75) 1.00 2010-2015 Hispanic 1,767 2.92 (2.78, 3.06) 1.13 (1.04, 1.21) 0.0019 2004-2009 1,467 2.68 (2.54, 2.83) 1.00 2010-2015 2,188 2.97 (2.84, 3.10) 1.11 (1.03, 1.19) 0.0046 Rates are per 100,000 and age-adjusted to the 2000 U.S. Standard Population. Abbreviations: IR, incidence rate; IRR, incidence rate ratio; CI, confidence interval; NHW, non-Hispanic White; NHB, non-Hispanic Black; NHO, non-Hispanic Other.
Table S2. Comparisonsa of minimally-adjusted mean APC expressionb in the normal-appearing colorectal mucosa of sporadic colorectal adenoma patients (n = 104), by selected participant characteristics Characteristics n Age (years) Whole crypt, mean (OD) 95% CI Proportional differencec (%) P-value Upper 40% of crypts, mean (OD) 95% CI Proportional differencec (%) P-value Lower 60% of crypts, mean (OD) 95% CI Proportional differencec (%) P-value 47 - 54 34 2,502 (2,148, 2,856) - 979 (817, 1,141) - 1,389 (1,157, 1,621) - 55 - 62 35 2,576 (2,224, 2,928) 3.0 1,040 (879, 1,201) 6.3 1,384 (1,153, 1,615) -0.3 63 - 75Sex Male 35 48 2,457 2,714 (2,106, 2,808) (2,338, 3,089) -1.8 - 0.88 1,026 1,074 (866, 1,186) (905, 1,242) 4.8 - 0.68 1,275 1,483 (1,045, 1,505) (1,261, 1,706) -8.2 - 0.51 Female 56 2,338 (1,990, 2,685) -13.9 0.15 966 (810, 1,122) -10.0 0.36 1,231 (1,026, 1,437) -17.0 0.10 Regulard use of aspirin No 64 2,586 (2,267, 2,904) - 1,078 (933, 1,223) - 1,350 (1,141, 1,560) - Yes 40 2,465 (2,221, 2,708) -4.7 0.58 977 (866, 1,088) -9.4 0.30 1,346 (1,186, 1,506) -0.3 0.98 Regulard use of other NSAID No 69 2,488 (2,152, 2,824) - 953 (801, 1,106) - 1,395 (1,175, 1,475) - YesCurrently smoke No 35 96 2,523 2,538 (2,293, 2,754) (2,349, 2,726) 1.4 - 0.87 1,048 1,029 (943, 1,152) (943, 1,115) 9.9 - 0.34 1,324 1,358 (1,172, 1,475) (1,234, 1,482) -5.2 - 0.61 Moderate 38 2,545 (2,204, 2,886) 4.9 1,027 (872, 1,183) 1.6 1,366 (1,143, 1,589) 8.4 High 27 2,518 (2,206, 2,830) 3.8 0.74 1,002 (859, 1,144) -1.0 0.91 1,375 (1,171, 1,580) 9.1 0.52 Body mass index (kg/m2) <25.0 22 2,477 (2,047, 2,907) - 986 (789, 1,182) - 1,360 (1,077, 1,642) - 25.0 - 29.9 43 2,575 (2,270, 2,880) 4.0 1,046 (907, 1,186) 6.1 1,379 (1,179, 1,579) 1.4 ≥30 Total energy, tertiles 1 39 34 2,461 2,813 (2,139, 2,782) (2,476, 3,149) 0.1 - 0.89 999 1,116 (852, 1,146) (960, 1,271) 1.4 - 0.99 1,307 1,548 (1,096, 1,518) (1,327, 1,768) -3.9 - 0.73 2 35 2,355 (2,017, 2,692) -16.3 937 (781, 1,094) -16.0 1,279 (1,058, 1,500) -17.4 3 Saturated fat, tertiles 1 35 34 2,388 2,756 (2,057, 2,719) (2,424, 3,089) -15.1 - 0.08 1,003 1,116 (850, 1,156) (961, 1,270) -10.1 - 0.31 1,230 1,482 (1,014, 1,447) (1,266, 1,698) -20.5 - 0.05 2 35 2,571 (2,238, 2,905 -6.7 974 (820, 1,129) -12.7 1,461 (1,244, 1,678) -1.4 3 Total fat, tertiles 1 35 34 2,203 2,602 (1,844, 2,562) (2,267, 2,938) -20.1 - 0.04 960 1,047 (794, 1,126) (891, 1,203) -14.0 - 0.17 1,094 1,406 (861, 1,327) (1,189, 1,623) -26.2 - 0.03 2 35 2,667 (2,335, 2,999) 2.5 1,027 (873, 1,18...
Table S2. Concordance and agreement (Xxxxx’x kappa) between tuberculin skin testing and QuantiFERON-TB Gold In Tube, considering ≥5 mm a TST positive in non- BCG-vaccinated and ≥10 mm in BCG-vaccinated children. result Positive Negative Concordance (%) (standard error) Overall population Positive 6 13 74.5 0.37(0.117) Negative 0 32 Non-BCG-vaccinated Positive 4 10 74.4 0.34(0.135) Negative 0 25 BCG-vaccinated Positive 2 3 0.44 Group of study TST QFN-G-IT result Overall Xxxxx’x kappa Negative 0 7 (0.233) TST: Tuberculin skin testing; QFN-G-IT: QuantiFERON-TB Gold In Tube; CI: Confidence interval; BCG: Mycobacterium bovis bacillus Xxxxxxxx-Xxxxxx testing and QuantiFERON-TB Gold In Tube, considering ≥10 mm a TST positive regardless of BCG vaccination status. result Positive Negative Concordance (%) (standard error) Overall population Positive 5 6 86% 0.55 Negative 0 (0.151) 32 Non-BCG-vaccinated Positive 3 4 0.54 Negative 0 87.5% (0.191) 25 BCG-vaccinated Positive 2 2 0.56 Negative 0 81.8% 7 (0.253) Group of study TST QFN-G-IT result Overall Xxxxx’x kappa
Table S2. Detection of CLL recurrence by quantitative real-time PCR Months After End of CFAR Treatment Donor CLL HCDR3 (CT ) GAPDH (CT) ΔCT Δ(ΔCT) Fold Change CLL HCDR3 Detection 38 not detectable 18.7 ± 0.1 0.00 0 0 negative 51 37.48 25.4 ± 0.4 12.10 2.02 0.25 weak positive 56 26.4 ± 0.1 18.4 ± 0.2 8.02 -2.02 4.05 positive Table S2: Detection of CLL recurrence by quantitative real-time PCR. Cryopreserved MNCs from the CLL donor after treatment were analyzed by qPCR for the presence of CLL donor HCDR3 transcript. Each time point is calculated as months after end of CFAR treatment regimen. The CT , ΔCT, and Δ(ΔCT) of the qPCR reaction using the CLL donor HCDR3-specific probe and GAPDH probes were used to calculate the fold change in the CLL donor HCDR3 transcript relative to the GAPDH endogenous control. Data generated by X-J. Yan. References
Table S2. Experiment parameters of Alice—Bob channel of OUTH-QDS illustrated in Fig. 4 of the main text.
Table S2. Inter-rater agreement a according to RSNA imaging classification for COVID-19 pneumonia diagnosis (continued).
Table S2. Inter-rater agreement a according to RSNA imaging classification for COVID-19 pneumonia diagnosis. Observer 1 - first analysis vs. Observer 2 - first analysis RSNA CT classification, No. (%) Negative Typical Indeterminate Atypical Total P value Xxxxx’x kappa Negative 24(15.1) 0(0.0) 3(1.9) 5(3.1) 32(20.1) .007 0.744 Typical 0(0.0) 77(48.4) 2(1.3) 0(0.0) 79(49.7) Indeterminate 0(0.0) 5(3.1) 18(11.3) 10(6.3) 33(20.8) Atypical 1(0.6) 0(0.0) 1(0.6) 13(8.2) 15(9.4) Total 25(15.7) 82(51.6) 24(15.1) 28(17.6) 159(100.0) Observer 1 - first analysis vs. Observer 2 - second analysis RSNA CT classification, No. (%) Negative Typical Indeterminate Atypical Total P value Xxxxx’x kappa Negative 24(15.1) 1(0.6) 4(2.5) 7(4.4) 36(22.6) .001 0.725 Typical 0(0.0) 77(48.4) 2(1.3) 0(0.0) 79(49.7) Indeterminate 0(0.0) 4(2.5) 17(10.7) 9(5.7) 30(18.9) Atypical 1(0.6) 0(0.0) 1(0.6) 12(7.5) 14(8.8) Total 25(15.7) 82(51.6) 24(15.1) 28(17.6) 159(100.0) Observer 1 - second analysis vs. Observer 2 - first analysis RSNA CT classification, No. (%) Negative Typical Indeterminate Atypical Total P value Xxxxx’x kappa Negative 26(16.4) 0(0.0) 0(0.0) 1(0.6) 27(17.0) .05 0.772 Typical 0(0.0) 78(49.1) 3(1.9) 0(0.0) 81(50.9) Indeterminate 4(2.5) 1(0.6) 21(13.2) 4(2.5) 30(18.9) Atypical 2(1.3) 0(0.0) 9(5.7) 10(6.3) 21(13.2) Total 32(20.1) 79(49.7) 33(20.8) 15(9.4) 159(100.0) (continued)
Table S2. Measurement Summary of 3-Facet RSM (Integrated Data, All Scorers) Facet N Measure M(SD) Measure Range Infit Range Outfit Range Sep. Strata Rel. Persons 318 0.09 (1.57) -4.90 – 4.16 0.39 – 2.25 0.24 – 7.89 6.91 0.98 Scorers 5 0.00 (0.08) -0.10 – 0.11 0.76 – 1.12 0.94 – 1.33 2.32 0.84 Items 30 0.00 (0.99) -2.36 – 1.46 0.70 – 2.08 0.66 – 4.98 17.14 1.00
Table S2. Platelet P-selectin mean fluorescent intensity (MFI) under basal and stimulated conditions, in whole blood collected into either BD Vacutainers containing 0.109mol/l buffered sodium citrate or manual syringes preloaded with 0.109mol/l buffered sodium citrate. Syr: syringe driven aspiration; Vac: vacutainer driven aspiration; ADP: adenosine diphosphate. Values are shown as mean and 95% CI. Significance at P<.00125 (after Bonferroni correction).
